FDA revokes breast cancer indication for bevacizumab
November 18th 2011FDA Commissioner Margaret A. Hamburg, MD, announced the agency's decision to revoke the breast cancer indication for bevacizumab (Avastin), noting that the benefits do not outweigh the potentially life-threatening side effects, such as heart attack or heart failure, high blood pressure, bleeding and hemorrhaging, and the development of perforations in different parts of the body, such as the nose, stomach, and intestines.
FDA approves bupivacaine hydrochloride injection, USP
October 20th 2011FDA has approved bupivacaine hydrochloride injection, USP (Sagent and Strides Arcolab), a local or regional anesthetic, for use in surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.
Overweight children have increased blood pressure risk, study finds
October 18th 2011Children who are overweight or obese have 3 times as much risk of high blood pressure as children of normal weight have, reported a study published recently in Hypertension: Journal of the American Heart Association.
The pharmacist and MTM services
October 15th 2011^MTM services are additional to provision of a drug product and include a broad range of pharmacists' activities within the scope of pharmacy practice. ^An example of MTM includes creating a medication treatment plan. ^Another example is monitoring and evaluating a patient's response to therapy.